TrialPath

69 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

62 studies on the map

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder — University of Alabama - Huntsville Regional Medical Campus /ID# 267818, HuntsvilleA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamStudy of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, BirminghamA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyStudy of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, ChandlerRE104 Safety and Efficacy Study in Generalized Anxiety Disorder — Lighthouse Psychiatry, GilbertPlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Novartis Investigative Site, BirminghamA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Allervie Clinical Research, BirminghamStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Enveda Investigative Site, BirminghamA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Atd002 52021, OceansideA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterA Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder — Vistagen Clinical Site, Sherman OaksA Study of NTX-1472 in Social Anxiety Disorder — SOAR Clinical Study Site, EncinoA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleSleep, Dreaming, and Virtual Reality for Mental Health — Northwestern University, EvanstonA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattlePharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, BoulderPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonPromoting Active Therapy: Path to Wellness — Kansas State University, ManhattanLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesEfficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder — McLean Hospital, BelmontEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoPsilocybin-Assisted Therapy for Intergenerational Trauma — The Parsons Research Center for Psychedelic Healing, New YorkPharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiFeasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer — Cedars-Sinai Medical Center, Los AngelesGaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety — National Institutes of Health Clinical Center, BethesdaInvestigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults — Southwest Autism Research and Resource Center, PhoenixStudy of Dextromethorphan in OCD and Related Disorders — Stanford University, StanfordTrial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders. — University of Cincinnati, CincinnatiEvaluating Buspirone to Treat Opioid Withdrawal — Kahlert Institute for Addictino Medicin, BaltimoreCannabidiol Effects on Learning and Anxiety — University of Connecticut, StorrsSelf-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy — Beth Israel Deaconess Medical Center, BostonDupixent and Narrowband UVB for Atopic Dermatitis — Eczema Treatment Center of New Jersey, East WindsorDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaEffects of Treatments on Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis — Lurie Children's Hospital/Northwestern University, ChicagoTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — ALS Global, IrvingEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborMolecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San Francisco